welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
Assessment of Cardiopulmonary Function in Duchenne Muscular Dystrophy
study id #: NCT02195999
condition: Muscular Dystrophy, Duchenne
This study seeks to develop and validate non-invasive assessments of cardiac and respiratory muscles with magnetic resonance imaging (MRI) to better predict the natural disease progression of Duchenne muscular dystrophy (DMD) in affected individuals over time, as well as determine whether peripheral skeletal muscle dysfunction can predict cardiopulmonary dysfunction. The central hypothesis is that non-invasive MRI measures of the heart, muscle, and peripheral skeletal muscles can sensitively predict future cardiopulmonary decline.
Magnetic Resonance Imaging (MRI), Pulmonary Function Testing (PFT), Metabolic Exercise Testing using stationary bicycle, Echocardiogram
mechanism of action: No pharmaceutical intervention
last updated: July 08, 2019
start date: December 2013
estimated completion: March 6, 2019
size / enrollment: 9
study description: Magnetic Resonance Imaging (MRI) of the heart and breathing muscles, special breathing tests (called pulmonary function testing), special exercise tests (using a stationary bike), and possibly an echocardiogram (ultrasound of the heart, commonly known as an "echo") will be completed up to 4 times per year for up to 4 years. Most participants will complete testing once or twice each year; however, some participants will be asked to repeat some of the tests twice during each visit.
- Magnetic Resonance (MRI) T2 and Magnetic Resonance Spectroscopy (MRS) [ Time Frame: up to 4 years ]
The MRI T2 and MRS will be used as a noninvasive marker of myocardial damage/inflammation of participants of this study as an early detection for DMD.
- Pulmonary Function Testing (PFT) [ Time Frame: up to 4 years ]
Non-invasive breathing tests that characterize respiratory muscle function, as well as lung compliance and physiology.
- Metabolic Exercise Testing (exercise capacity and MVO2) [ Time Frame: up to 4 years ]
With the use of metabolic exercise testing, the aim is to correlate changes in cardiopulmonary function with decline in peripheral skeletal muscle function in individuals with DMD. Metabolic exercise testing includes measuring exercise capacity and maximum oxygen consumption (MVO2).
- Multiple-echo Dixon [ Time Frame: up to 4 years ]
The echocardiogram performed with the multiple-echo Dixon method helps to assess participants cross-sectionally and longitudinally for variations and changes in myocardial structure. This method and MRS will also be used for fat fraction determination.
• 5-15 years old at the time of enrollment
• Diagnosed with DMD (as defined by parent project)
• Written parental informed consent (and assent where appropriate) before any study procedures take place
• Contraindication to an MRI examination
• Presence of a secondary condition that impacts muscle function or metabolism, that leads to developmental delay or impaired motor control, or that is not stable
• Participant is unable to comply with study requirements
• Congenital structural abnormality of the heart, repaired or unrepaired
• Clinically contraindicated participation
Wave Life Sciences Receives US Orphan Drug and Rare Pediatric Disease Designations for WVE-210201Wave Life Sciences Ltd., a biotechnology...
Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD)The objective of this study is to assess...
Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)This is a Phase 2, open-label, single ar...
A Study to Assess the Efficacy and Safety of MNK-1411 in Duchenne Muscular DystrophyThis is a multicenter, double blind, pla...
Large-scale serum protein biomarker discovery in Duchenne muscular dystrophySerum biomarkers in Duchenne muscular dy...
Improved Muscle Function in Duchenne Muscular Dystrophy Through L-Arginine and MetforminThe purpose of the study is to show that...
Catabasis Quarterly: Updates on edasalonexent and clinical trialsHappy New Year! As 2019 kicks off, our P...
For Many Boys With Duchenne Muscular Dystrophy, Bright Hope Lies Just Beyond ReachLucas was 5 before his parents, Bill and...
Rare diseases require unique approaches in clinical trial designThere are 7,000 known rare diseases and ...